Dr Kristian Sandberg was elected as new member of the board at an extraordinary general meeting held in Umeå on March 3, 2020.Dr Kristian Sandberg is an associate professor in immunology and an experienced leader in the pharmaceutical industry’s research and development. Sandberg has over 20 years’ experience from AstraZeneca in various functions within R&D, [...]
After an intensive and targeted work, the cell line development of our lead drug candidate SOL-116 has been finalized. Now the production optimization and scale up has been initiated and that will provide access of non-GMP and GMP material during 2020. That will enable toxicity studies and start of clinical trials as planned during 2021.Read [...]
Lipum has developed a biological drug candidate for treatment of chronic inflammatory diseases and aim for a better treatment of juvenile idiopathic arthritis (JIA), that affects children. Therefore, the scientific advisory board of the company is now strengthened with Anders Fasth, senior professor of pediatric immunology at the University of Gothenburg and a senior consultant [...]
Life Science industry leaders, financing experts and qualified investors gather in Lund. Welcome to meet us at Biostock Life Science Summit, october 23th-24th.Register here: https://www.eventbrite.com/e/biostock-life-science-summit-2019-tickets-73953881049
Today, our COO, Pernilla Abrahamsson, is traveling to Paris to participate at French-Swedish Life Science Days 2019.The goal of the conference is to establish new contacts and identify business and collaboration opportunities. The conference will gather early stage and highly innovative medtech and biotech companies from Sweden and France, French and Swedish life science investors [...]
On this autumn’s first BioStock Live Investor Event you have the chance to listen to presentations and talk with representatives from five life science companies.On August 27, Lipums CEO Einar Pontén will present our recent progress towards a novel treatment of chronic inflammatory diseases. The presentation will be broadcasted live on the web from 10am. Participating [...]
Therapies for autoimmune diseases are available but do not work for all patients, and when they do, side effects can be severe. There is a strong need for new therapies and therefore there is a large market potential, especially for treatments targeting rheumatoid arthritis and multiple sclerosis. In this third segment of the article series, BioStock [...]
Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, a company developing treatments for chronic inflammatory diseases.Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, [...]
Horizon 2020, the EU framework program for research and development, will grant 2.2 million euros to Lipum’s ongoing development of a biological pharmaceutical for treatment of chronic inflammatory diseases.Lipum has identified the novel target molecule Bile Salt-Stimulated Lipase (BSSL). Preclinical studies have very successfully verified the concept in several well-established models for autoimmune chronic inflammatory [...]